PURPOSE To produce definitions based on serial CA 125 levels to measure response of
ovarian carcinoma in patients receiving first-line chemotherapy. PATIENTS AND METHODS …

Background There is a need to delineate how the best available serum marker for ovarian
cancer, CA 125 should be used in monitoring the treatment of individual patients, and in …

Background Many studies have shown that CA 125 levels frequently rise prior to clinical
evidence of progression of ovarian cancer. For clinical trials an accepted definition of …

This retrospective multicentric study assessed the prognostic value of the serum CA 125
assay and the common clinicopathological variables in 225 patients with advanced …

Thirty-one patients with ovarian cancer were monitored with the CA 125 antigenic
determinant in the interval between cytoreductive surgery and the completion of sub …

BACKGROUND: The objective of the current study was to determine the prognostic
significance of a pretreatment serum CA 125 level in patients with advanced epithelial …

CA 125 was measured during early chemotherapy in 121 patients with FIGO stage III or IV
ovarian cancer to investigate if the antigen could be used as a prognostic parameter. CA …

We read with much interest the article by Therasse et al.(1) on the new Response Evaluation
Criteria in Solid Tumors Group (RECIST) in the Journal. In the RECIST, the definition of …

The purpose of this article is to demonstrate how CA-125 could be used in clinical trials to
ascertain the efficacy of new drugs for ovarian cancer. Studies that have investigated the use …

Serum CA 125 levels were obtained from 55 women with epithelial ovarian cancer before a
second-look surgical procedure and serially thereafter. All patients were clinically and …